Clinical and biological features of CLL patients
| . | pERK1/2(+) . | pERK1/2(−) . | P . |
|---|---|---|---|
| CD38 positive (≥30%) | 10.5% (2/19) | 44.4% (12/27) | .01 |
| Unmutated IGHV genes | 42.1% (8/19) | 57.7% (15/26) | .4 |
| ZAP70 positive (≥20%) | 35.3% (6/17) | 66.7% (18/27) | .02 |
| Disease progression | 26.7% (4/15) | 76.5% (13/17) | .007 |
| . | pERK1/2(+) . | pERK1/2(−) . | P . |
|---|---|---|---|
| CD38 positive (≥30%) | 10.5% (2/19) | 44.4% (12/27) | .01 |
| Unmutated IGHV genes | 42.1% (8/19) | 57.7% (15/26) | .4 |
| ZAP70 positive (≥20%) | 35.3% (6/17) | 66.7% (18/27) | .02 |
| Disease progression | 26.7% (4/15) | 76.5% (13/17) | .007 |